De mest almindelige rapporterede bivirkninger var infusionsrelaterede reaktioner, som optrådte hos 13, 7% af patienter, der blev behandlet med Replagal i kliniske studier.
The most commonly reported undesirable effects were infusion associated reactions, which occurred in 13.7% of patients treated with Replagal in clinical trials.